000168557 001__ 168557
000168557 005__ 20240229133611.0
000168557 0247_ $$2doi$$a10.1038/s41375-021-01235-z
000168557 0247_ $$2pmid$$apmid:33911178
000168557 0247_ $$2ISSN$$a0887-6924
000168557 0247_ $$2ISSN$$a1476-5551
000168557 0247_ $$2altmetric$$aaltmetric:104938415
000168557 037__ $$aDKFZ-2021-00974
000168557 041__ $$aEnglish
000168557 082__ $$a610
000168557 1001_ $$0P:(DE-He78)4f0e4e5d91743a1f23a60da2d5afe928$$aKiehlmeier, Sandra$$b0$$eFirst author$$udkfz
000168557 245__ $$aIdentification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
000168557 260__ $$aLondon$$bSpringer Nature$$c2021
000168557 3367_ $$2DRIVER$$aarticle
000168557 3367_ $$2DataCite$$aOutput Types/Journal article
000168557 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642077617_474
000168557 3367_ $$2BibTeX$$aARTICLE
000168557 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168557 3367_ $$00$$2EndNote$$aJournal Article
000168557 500__ $$a#EA:A380#LA:A380# / 2021 Nov;35(11):3127-3138
000168557 520__ $$aDeregulation of the EVI1 proto-oncogene by the GATA2 distal hematopoietic enhancer (G2DHE) is a key event in high-risk acute myeloid leukemia carrying 3q21q26 aberrations (3q-AML). Upon chromosomal rearrangement, G2DHE acquires characteristics of a super-enhancer and causes overexpression of EVI1 at 3q26.2. However, the transcription factor (TF) complex of G2DHE remains poorly characterized. The aim of this study was to unravel key components of G2DHE-bound TFs involved in the deregulation of EVI1. We have identified several CEBPA and RUNX1 binding sites to be enriched and critical for G2DHE function in 3q-AML cells. Using ChIP-SICAP (ChIP followed by selective isolation of chromatin-associated proteins), a panel of chromatin interactors of RUNX1 and CEBPA were detected in 3q-AML, including PARP1 and IKZF1. PARP1 inhibition (PARPi) caused a reduction of EVI1 expression and a decrease in EVI1-G2DHE interaction frequency, highlighting the involvement of PARP1 in oncogenic super-enhancer formation. Furthermore, 3q-AML cells were highly sensitive to PARPi and displayed morphological changes with higher rates of differentiation and apoptosis as well as depletion of CD34 + cells. In summary, integrative analysis of the 3q-AML super-enhancer complex identified CEBPA and RUNX1 associated proteins and nominated PARP1 as a potential new therapeutic target in EVI1 + 3q-AML.
000168557 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000168557 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168557 7001_ $$0P:(DE-He78)ee67362429cf58e34b8e254dc124302b$$aRafiee, Mahmoud-Reza$$b1
000168557 7001_ $$0P:(DE-He78)277add45f831355e9453b41e651f6411$$aBakr, Ali Mohyeldin Ali$$b2$$udkfz
000168557 7001_ $$0P:(DE-He78)07af613eea059030daaed3bde1fd1ce7$$aMika, Jagoda$$b3$$udkfz
000168557 7001_ $$0P:(DE-He78)0d2d2e2cf00b6cd853cb19769ce54aca$$aKruse, Sabrina$$b4$$udkfz
000168557 7001_ $$0P:(DE-He78)95a3e9a95c4a7b333969943b2bd26852$$aMüller, Judith$$b5$$udkfz
000168557 7001_ $$0P:(DE-He78)5525104273ea624741fada1c89dd1669$$aSchweiggert, Sabrina$$b6$$udkfz
000168557 7001_ $$aHerrmann, Carl$$b7
000168557 7001_ $$0P:(DE-He78)a63bd9276ca497fcfcd476478727a6dc$$aSigismondo, Gianluca$$b8$$udkfz
000168557 7001_ $$0P:(DE-He78)141ce740f5d881812d2675147b72ecaf$$aSchmezer, Peter$$b9$$udkfz
000168557 7001_ $$0P:(DE-He78)939d5891259c638c1ab053b1456a578c$$aKrijgsveld, Jeroen$$b10$$udkfz
000168557 7001_ $$0P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aGröschel, Stefan$$b11$$eLast author$$udkfz
000168557 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/s41375-021-01235-z$$n11$$p3127-3138$$tLeukemia$$v35$$x1476-5551$$y2021
000168557 909CO $$ooai:inrepo02.dkfz.de:168557$$pVDB
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4f0e4e5d91743a1f23a60da2d5afe928$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)277add45f831355e9453b41e651f6411$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)07af613eea059030daaed3bde1fd1ce7$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0d2d2e2cf00b6cd853cb19769ce54aca$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)95a3e9a95c4a7b333969943b2bd26852$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5525104273ea624741fada1c89dd1669$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a63bd9276ca497fcfcd476478727a6dc$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)141ce740f5d881812d2675147b72ecaf$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)939d5891259c638c1ab053b1456a578c$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000168557 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000168557 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000168557 9130_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000168557 9141_ $$y2021
000168557 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2019$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-29
000168557 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bLEUKEMIA : 2019$$d2021-01-29
000168557 9201_ $$0I:(DE-He78)A380-20160331$$kA380$$lNWG Molekulare Leukämogenese$$x0
000168557 9201_ $$0I:(DE-He78)B230-20160331$$kB230$$lB230 Proteomik$$x1
000168557 9201_ $$0I:(DE-He78)B370-20160331$$kB370$$lEpigenomik$$x2
000168557 980__ $$ajournal
000168557 980__ $$aVDB
000168557 980__ $$aI:(DE-He78)A380-20160331
000168557 980__ $$aI:(DE-He78)B230-20160331
000168557 980__ $$aI:(DE-He78)B370-20160331
000168557 980__ $$aUNRESTRICTED